Home > About Us > Board of Managers & Advisory Board

Board of Managers

C. Dean Maglaris, CEO, Chairman of the Board of Managers. Mr. Maglaris is an experienced senior executive in the pharmaceutical industry, having spent over 33 years with Pfizer Inc. in leadership positions in marketing, product and business development and general management. His experience covered the spectrum of major therapeutic areas in pharmaceuticals plus a wide array of medical device markets in the U.S. and worldwide. As Group Vice President and General Manager, he was instrumental in the development and launch of several products that became major successes, with several achieving annual sales in excess of $1.0 billion each. Mr. Maglaris has been a member of a number of associations, including the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He is a past Trustee and Chair of the Board of Trustees of the University of Vermont, a past member and officer of the Board of Trustees of the New Canaan Country School and serves as Chariman of the Board of Directors of the AmeriCares Foundation. He holds a B.S. degree from the University of Vermont and an MBA from Northeastern University.

Buck Griswold (E. Bulkeley Griswold), Managing Director, Senior Principal, Centripetal Capital Partners, has over 40 years of experience in investments. As Vice President of the Phoenix Mutual Life Insurance Company from 1970 to 1977, Mr. Griswold managed the administration and investment decisions for a $1.5 billion portfolio in public and private fixed income and equities. He subsequently joined General Electric Investment Company (GEIC), the internal investment management company for GE pension assets and other affiliated GE portfolios. Mr. Griswold was Executive Vice President Trustee responsible a $15 billion portfolio of assets including corporate and municipal bonds, private placements, real estate and short-term investments. From 1983 to 1998, Mr. Griswold was a part owner of Marketing Corporation of America (MCA), an integrated marketing services firm. He led the company's venture capital group as President and General Partner of MarketCorp Venture Associates, LP - a $66 million venture capital fund jointly formed with MCA. In 1998, he founded L&L Capital Partners, LLC to provide management consulting and financial advisory services to venture-backed companies. He received a BS at the University of Maryland and an MBA from University of Connecticut.

Joseph J. Rucci, Jr., serves as an outside manager on the Company's Board of Managers and is also a member of the Compensation Committee. Mr. Rucci is founder/member of the Rucci Law Group with offices in Connecticut. He concentrates in the areas of business law, banking and not-for-profit organizations. He is admitted to practice before the Connecticut Bar, the United States District Court for Connecticut and the United States Court of Appeals for the First Circuit, as well as the United States Supreme Court. He is a director and chairman of the Governance Committee of the AmeriCares Foundation, Inc.; a director of the Pear Tree Point School Foundation, Inc.; a member of Rotary International and of the Sovereign Order of Malta. Mr. Rucci has been recognized for his expertise by The Martindale Hubbell Bar Register of Preeminent Lawyers and the National Directory of Who's Who on Executives and Professionals. Mr. Rucci was awarded a Juris Doctorate from the Villanova University School of Law in 1966 and graduated from Fairfield University in 1963.

Frederick W. Telling, Ph.D., Prior to retiring from Pfizer in June 2007 after 30 years, Fred was elected a Corporate Vice President of Pfizer Inc and its Vice President of Corporate Strategic Planning and Policy in October 1994. He oversaw the company's realignment and focus on its human and animal health business - divesting its Food Science and Medical Technology groups, while acquiring Warner Lambert, Pharmacia and various consumer product brands. Concurrently, Fred was responsible for the company's policy development and he represented the company in many industry related outside Boards, including BIO where he served on its Board for over 10 years.

Dr. Telling is currently the Chairman of Oragenics in Tampa, Florida and a Director of Cell Therapeutics Inc. based in Seattle, Washington and Eisai N.A. Inc. in Woodcliff Lake, New Jersey. Fred chairs the Compensation Committee and serves on the Audit Committee of both Cell Therapeutics and Oragenics.

Dr. Telling is a member of the Board of the United Hospital Fund and an emeritus member of the Boards of several organizations with which he remains involved - the National March of Dimes Foundation, EAA, ORBIS, and the Smithsonian National Air & Space Museum. Fred is the President of the T-6 Racing Association and a member of The Metropolitan Club of Washington, DC.

Dr. Telling received his BA from Hamilton College and his Master's of Industrial and Labor Relations and Ph. D. in Economics and Public Policy from Cornell University.

Cassandra Klimp., An initial investor and a founding manager of Cytogel Pharma is a partner of Meridian Partners LLC, a technology venture advisory firm and the Classic Motorcar Investment Fund in Connecticut with 30 years of experience in corporate banking, project management and entrepreneurship. Early in her career she was affiliated with US Bancorp in Minneapolis as the corporate lender to multibank holding companies throughout the Midwest. She has performed a broad range of advisory, managerial, financial and project related functions both for profit and non-profit organizations. Ms. Klimp was a long time member of the board of Waveny Care Center and the New Canaan Historical Society. She co-chaired the planning and construction of a state of the art Alzheimer’s community at Waveny Care Center that received national recognition. She is a native of Minnesota and holds a BS and post graduate work in the sciences from the University of Minnesota

Advisory Board

Russell K. Portenoy, M.D., Medical Advisor: Dr. Russell Portenoy is Chairman and the Gerald J. and Dorothy R. Friedman Chair in Pain Medicine and Palliative Care of the Department of Pain Medicine and Palliative Care at the Beth Israel Medical Center in New York, and Professor of Neurology and Anesthesiology at the Albert Einstein College of Medicine. He is an immediate past-President of the American Academy of Hospice and Palliative Medicine and a past President of the American Pain Society. He is the recipient of the Wilbert Fordyce Award for Lifetime Excellence in Clinical Investigation, the Distinguished Service Award from the American Pain Society, the Founder's Award from the American Academy of Pain Medicine, and the Bonica Award from the Eastern Pain Association. He serves on the Board of Directors of the American Pain Foundation and chairs both the medical forum of the National Hospice Work Group and the Committee on Hospice and Palliative Medicine of the Accreditation Council for Graduate Medical Education. Dr. Portenoy's research has focused on clinical trials of analgesic drugs, opioid pharmacology, symptom measurement, and quality of life assessment. He is editor-in-chief of the Journal of Pain and Symptom Management.

Robert F. Kaiko, Ph.D., Dr. Kaiko recently joined Cytogel Pharma Advisory Board as a scientific and clinical consultant, advising the Company on the development of its novel endomorphin compound, Cyt-1010.

Dr. Kaiko began his career in the industry when he joined The Purdue Frederick Company in 1985 as associate medical director. He has held a number of positions of increasing responsibility, including vice president of clinical research and vice president, R&D portfolio development. He retired from Purdue Pharma in 2013. While at Purdue he contributed to the clinical development of controlled-release oral morphine (MS Contin), led the development of controlled-release oral oxycodone (OxyContin) and its recent reformulation, and initiated the clinical development of transdermal buprenorphine (BuTrans) and other analgesics.

Pain treatment, specifically, opioid analgesia, has been a focus during his career, and Dr. Kaiko is an inventor on a number of patents in this area. He has published 100 peer reviewed articles and almost 200 abstracts.

Dr. Kaiko served as a board member for Pain and Analgesia and PRN Forum and was a contributing editor for the Journal of Pain and Symptom Management and Cancer Pain Release. He was a reviewer for the Journal of Pharmaceutical Sciences and several other research publications. He has also served as president and board member of the Eastern Pain Association.

Dr. Kaiko has consulted for the Food and Drug Administration, the Drug Abuse Advisory Board, the Federal Trade Commission, and the World Health Organization. He was also a grant reviewer and site visitor for the National Cancer Institute and the Veteran's Administration.

awarded the Pharmacology Prize from the School. He obtained his Ph.D. in pharmacology in 1974 from Cornell University Graduate School of Biomedical Sciences in New York City. He then became a research associate at Sloan-Kettering Institute for Cancer Research in the Analgesic Studies Section. Dr. Kaiko was also a postdoctoral research fellow, instructor and adjunct assistant professor at Cornell University Graduate School of Biomedical Sciences in the Department of Pharmacology.

Bob A. Rappaport, M.D., Dr. Rappaport joined the Cytogel Advisory Board as a Consultant in 2015, having retired from the FDA in October of 2014. Dr. Rappaport was Director of the Division of Anesthesia, Analgesia, and Addiction Products at the FDA for 12 years where he led a large team of physicians, scientists and regulatory project managers to oversee the investigation, development, approval, continued safety, and safe use of drug products to treat pain and addiction disorders, as well as drug products used in the setting of clinical anesthesia. He was an advocate for the development of novel analgesic, anesthetic and addiction drug products throughout his tenure, and instituted new standards for the study of these drugs. He has also been an active member of the IMMPACT consensus group since its inception. In 2010 he worked within FDA to build the ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks) public-private-partnership, which was initially designed to advance the field of analgesic drug development by improving analgesic clinical study design, conduct and analysis. This highly successful initiative was later expanded to include improving the study and development of anesthetics, and drugs to treat addiction and peripheral neuropathy. Dr. Rappaport was centrally involved with the FDA's continued efforts to encourage and assist in the development of abuse-deterrent opioid formulations, and with his staff he completed an updated guidance for the pharmaceutical industry on the development of analgesic drug products. In 2013, Dr. Rappaport received the Agency's Lifetime Achievement Award for his contributions to the anesthesia, analgesia, and addiction fields by accelerating the discovery and development of new drugs with improved efficacy and safety.

Dr. Rappaport graduated from and completed his medical training at The George Washington University School of Medicine and Health Sciences, and is board certified in neurology and sleep medicine. In May of this year Dr. Rappaport will receive the 2015 John and Emma Bonica Public Service Award at the annual meeting of the American Pain Society. The Bonica Award recognizes distinguished contributions to the field of pain through public education, dissemination of information, public service, or other efforts that further knowledge about pain.